+81.3%
RKT vs GSK
+65.8%
+15.5%
-55.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +0.5% | -0.5% | -0.2% |
| 7D | -9.0% | +1.1% | -10.1% | -9.3% |
| 30D | +30.2% | +6.3% | +23.9% | +28.1% |
| 3M | -8.8% | +1.8% | -10.7% | -9.3% |
| 6M | -0.9% | +1.7% | -2.6% | -1.7% |
| YTD | -29.2% | +6.5% | -35.7% | -30.2% |
| 1Y | -20.1% | +9.5% | -29.5% | -21.7% |
| 3Y | +81.3% | +65.3% | +16.0% | +79.6% |
| All | +81.3% | +65.8% | +15.5% | +79.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling